Last updated on February 2016

Treatment of SFA Lesions With 480 Biomedical STANZA Drug-Eluting Resorbable Scaffold (DRS) System

Brief description of study

An evaluation of the safety and performance of the STANZA Drug-eluting Resorbable Scaffold (DRS) system for the treatment of patients with obstructive superficial femoral artery disease.

Detailed Study Description

The STANZA DRS system is comprised of a controlled release paclitaxel-eluting bioresorbable scaffold and a delivery system used in the treatment of superficial femoral artery disease.

Clinical Study Identifier: NCT02097082

Contact Investigators or Research Sites near you

Start Over

Marianne Brodmann, MD

Universit ts Klinikum Graz
Graz, Austria
  Connect »

Martin Werner, MD

WGKK - Hanusch-Krankenhaus
Vienna, Austria
  Connect »

Florian Wolf, MD

Cardiovascular and Interventional Radiology- AKH
Vienna, Austria
  Connect »